A Bridge on Economic Issues between China and the World
Facebook 
Twitter 
Instagram
WeChat 
Email Most Popular
Fiscal Stimulus, Deposit Competition, and the Rise of Shadow Banking: Evidence from China
Viral V. Acharya, Jun Qian, Yang Su, Zhishu Yang, Apr 24, 2024The article reveals that the rise of shadow banking in China stems from the intensification of deposit competition after the global financial crisis, and analyzes the threat of small and medium-sized banks' disadvantage in this competition to the overall financial system.
Labor Market Discrimination against Family Responsibilities: A Correspondence Study with Policy Change in China
Haoran He, Sherry Xin Li, Yuling Han, Jan 24, 2024China shifted its controversial one-child policy (1979–2015) to a two-child policy in 2016. We take advantage of the unexpected timing of this policy change and the heterogeneities in the pre-change environment to investigate labor market discrimination against expected family responsibilities.
“To Go Electric or to Burn Coal? A Randomized Field Experiment of Informational Nudges”
Hanming Fang, King King Li, Peiyao Shen, Feb 07, 2024We conducted a randomized field experiment of informational nudges in northern China to investigate the potential obstacles that may hinder households from adopting cleaner heating, and evaluate the effectiveness of simple SMS nudges in encouraging the transition to electric heating.
Lucky Dragons
Chih Ming Tan, Xiao Wang, Xiaobo Zhang, Feb 21, 2024This article explores the intriguing connection between Chinese zodiac signs and parental investment in children’s development. Particularly, parents invest more in children born under the “lucky” sign of the dragon, potentially impacting their cognitive and noncognitive skills alike.
Improving Regulation for Innovation: Evidence from China’s Pharmaceutical Industry
Ruixue Jia, Xiao Ma, Jianan Yang, Yiran Zhang, Mar 06, 2024In 2015, China revamped its pharmaceutical regulations, drawing inspiration from the US, to accelerate drug approvals. Using data at the drug and firm levels during 2011–2021, this study reveals three key outcomes.
